Esculentoside A inhibits tumor necrosis factor, interleukin-1, and interleukin-6 production induced by lipopolysaccharide in mice

Pharmacology

Volumn 56, Issue 4, 1998, Pages 187-195

  Ju, Dian Wen ^a   Zheng, Qin Yue ^a   Cao, Xuetao ^a   Fang, Jun ^a   Wang, Hong Bin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anti inflammation; Esculentoside A; Interleukin 1; Interleukin 6; Tumor necrosis factor

Indexed keywords

ESCULENTOSIDE A; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; SAPONIN; SHANG LU; THIOGLYCOLIC ACID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHINESE HERB; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL DIVISION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; INTERLEUKIN-1; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED ICR; OLEANOLIC ACID; REGRESSION ANALYSIS; SAPONINS; SHOCK, SEPTIC; THYMUS GLAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031891807     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028197     Document Type: Article

References (34)

1. Zheng QY, Mai K, Pan XF, Yi YH: Anti-inflammatory effects of esculentoside A. Chin J Pharmacol Toxicol 1992;6:221-224.
2. Yi YH, Wang ZL: Study on the effective compounds in Phytolaca esculenta. Zhong Cao Yao 1984;15: 55-58.
3. Maestre P, Zarco C, Guerrero CG: Cooperation between tumor necrosis factor TNF and platelet-activating factor PAF in the inflammatory response. J Lipid Med 1990; 2(suppl):151-159.
4. Bertolini DR, Nedwin GE, Bringman TS, Smoth DD, Mundy GR: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factor. Nature 1986;319:516-518.
5. Arend WP, Dayer JM: Cytokine and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33:305-315.
6. Cutolo M, Accardo S, Villaggio B, Barone A, Sulli A, Balleari E, Bason C, Felli L, Granata OM, Amodio R, Castagnetta L: Androgen metabolism and inhibition of interleukin-1 synthesis in primary cultured human synovial macrophages. Mediat Inflam 1995;4:138-143.
7. Dinarello CA, Wollf SM: Role of interleukin-1 in disease. N Engl J Med 1993;328:106-113.
8. Jarvinen TAH, Moilanen T, Jarvinen TLH, Moilanen E: Nitric oxide mediates interleukin-1 induced inhibition of glycosaminoglycan synthesis in rat articular cartilage. Mediat Inflam 1995;4:107-111.
9. Kirkham B: Interleukin-1, immune activation pathways, and differentiation mechanisms in osteoarthritis and arthritis. Ann Rheum Dis 1991; 50:395-400.
10. Kishimoto T: The biology of interleukin 6. Blood 1989;74:1.
11. Hirano T: Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992; 62(suppl):60-65.
12. Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP: Interleukin 6 is expressed in high level in psoriatic skin and stimulates the proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989;86:6367-6371.
13. Shinmei M, Masuda K, Kikuchi T, Shimomura Y: Interleukin 1, tumor necrosis factor, and interleukin 6 as mediators of cartilage destruction. Semin Arthritis Rheum 1989;18: 27-32.
14. Oster W, Cicco NA, Klein H, Hirano T, Kishimoto T, Lindermann A: Participation of the cytokines IL-6, TNFα, and IL-1-secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest 1989; 84:451-457.
15. Takai Y, Seki N, Senoh H, et al: Enhanced production of interleukin-6 in mice with type II collagen-induced arthritis. Arthritis Rheum 1989;32:594-600.
16. van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB: Role of interleukin 1 IL-1, tumor necrosis factor a (TNFα) and interleukin 6 (IL-6), in cartilage proteoglycan metabolism and destruction: Effects of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995;38:164-172.
17. Libert C, Takahashi N, Cauwels A, Brouckaert P, Bluethmann H, Fiers W: Response of interleukin 6-deficient mice to tumor necrosis factor-induced metabolic changes and lethality. Eur J Immunol 1994;24: 2237-2242.
18. Schow SR, Joly A: N-Acetyl-leucinyl-leucinyl-norleucinal inhibits lipopolysaccharide-induced NF-kappaB activation and prevents TNF and IL-6 synthesis in vivo. Cell Immunol 1997;175:199-202.
19. Scholz W: Interleukin 6 in disease: Cause or cure? Immunopharmacology 1996;31:131-150.
20. Drazan KE, Wu L, Bullington D, Shaked A: Viral IL-10 gene therapy inhibits TNF-alpha and IL-1 beta, not IL-6, in the newborn endotoxemic mouse. J Pediatr Surg 1996;31: 411-414.
21. Ju DW, Zheng QY, Wang HB, Guan XG, Fang J, Yi YH: Inhibitory effects of esculentoside A on mouse macrophages and antibody production. Acta Pharm Sin 1994;29:252-255.
22. Engelberts I, von Asmuth EJU, van der Linden CJ, Buurman WA: The interrelation between TNF, IL-6, and PAF secretion induced by LPS in an in vivo and in vitro murine model. Lymphokine Cytokine Res 1991;10:127-131.
23. Ju DW, Zheng QY, Wang HB, Wang XF, Fang J: Effect of platelet-activating factor antagonist WEB 2086 on the production of TNF from murine peritoneal macrophages. Acta Pharm Sin 1993;28: 721-727.
24. Ju DW, Zheng QY, Wang HB, Fang J: Inhibitory effect of triazolodiazepine on mouse lymphocyte and peritoneal macrophages in vitro. Acta Pharm Sin 1994;15:65-68.
25. Ju DW, Zheng QY, Cao XT, Zheng QH, Guan XG, Wang HB: Effects of triazolodiazepine on the production of interleukin-6 from murine spleen cells and rabbit synovial cells in vitro. Mediat Inflam 1995;4:130-132.
26. Wang HB, Zheng QY, Qian DH: Effect of Phytolaca acinosa polysaccharide I on immune function in mice. Acta Pharm Sin 1993;14:243-246.
27. Madretsma GS, Donze GJ, van Dijk APM, Tak CJAM, Wilson JHP, Zijlstra FJ: Nicotine inhibits the in vitro production of interleukin 2 and tumor necrosis factor α by human mononuclear cells. Immunopharmacology 1996;35:47-51.
28. Fukuzawa M, Satoh J, Sagara M, Muto G, Muto Y, Nishimura S, Miyaguchi S, Qiang XL, Sakata Y, Nakazawa T, Ikehata F, Ohta S, Yoyota T: Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-in vitro and in vivo. Immunopharmacology 1997;36:49-55.
29. Siedlar M, Szczepanik A, Wiechiewicz J, Pituch-Noworolska A, Zembala M: Vancomycin down-regulates liposaccharide-induced tumor necrosis factor α (TNFα) production and TNF-mRNA accumulation in human blood monocytes. Immunopharmacology 1997;35:265-271.
30. Fang J, Zheng QY: Inhibitory effects of esculentoside A on platelet activating factor released from calcimycin induced rat peritoneal macrophages. Acta Pharm Sin 1991;26: 721-724.
31. Braquet P: PAF/cytokine auto-generated feed back networks in micro-vascular immune injury: Consequences in shock, ischemia and graft rejection. J Lipid Mediat 1989;1: 75-79.
32. Molnar-Kimber KL, Yonno L, Heaslip RJ, Weichman BM: Differential regulation of TNF- and IL-1 production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors. Mediat Inflam 1992;1:411-417.
33. Cavaillon JM: Contribution of cytokines to inflammatory mechanisms. Pathol Biol (Paris) 1993;41:799-811.
34. Barton BE, Jakway JP, Smith SR, Siegel MI: Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol 1991;13:251-261.